[Clinical and bacteriological substantiation of the use of cefoperazone/sulbactam in complex therapy of patients with pyo-destructive forms of lower respiratory tract infection (LRTI)].

Antibacterial therapy is the most important component of the complex management of pyo-destructive forms of LRTI. Since the microbial flora is rather variable and polymorphous, antibiotics used in the treatment of LRTI should be active against both aerobic (especially gramnegative) and anaerobic pathogens. The aim of the study was to prove, on the basis of the bacteriological and clinical findings, the validity of the use of cefoperazone/sulbactam (CS), the only inhibitor-protected cephalosporin, for the monotherapy of patients with LRTI.